Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoPrecise Antibodies Ltd.

< Previous 1 2 3 Next >
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
Tickers IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Resignation of Director
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.